Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818165 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases
A Phase 1 study, sponsored by Sorrento Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03818165 is a Phase 1 study that was terminated before completion, run by Sorrento Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT03818165, a Phase 1 study, was terminated before completion, sponsored by Sorrento Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is an open-label, single arm phase 1b safety study of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions for pancreatic carcinoma patients with carcinoembryonic antigen positive (CEA+) liver metastases resistant to standard therapy who meet all other eligibility criteria.
Interventions
- BIOLOGICAL CAR2 Anti-CEA CAR-T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2021-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03818165
The ClinicalTrials.gov registry entry for NCT03818165 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAR2 Anti-CEA CAR-T cells is the first listed.
NCT03818165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03818165 about?
NCT03818165 is a clinical study titled "Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases". This study is an open-label, single arm phase 1b safety study of CAR2 Anti-CEA CAR-T cell hepatic arterial infusions for pancreatic carcinoma patients with carcinoembryonic antigen positive (CEA+) liver metastases resistant to standard therapy who meet all other eligibility criteria.
What is the current status of trial NCT03818165?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-07-29. Estimated completion is 2021-05-21.
What interventions are being tested in trial NCT03818165?
The interventions under investigation include: CAR2 Anti-CEA CAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03818165?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.